カテゴリ： GlobalData, アメリカ, 企業調査

GlycoMimetics Inc (GLYC)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：GlycoMimetics Inc (GLYC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9814
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：55
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
GlycoMimetics Inc (GlycoMimetics) is a clinical-stage biotechnology company that research, develops and commercializes small molecule drugs. The company’s products comprise rivipansel (GMI-1070), under phase III clinical trial is an anti-inflammatory compound to treat vaso-occlusive crisis of sickle cell disease and blood cancers. It also provides GMI-1271, galectin inhibitors, GMI – 1359, GMI-1051 and research programs. GlycoMimetics designs and tests viral and bacterial entry inhibitors dendritic cell receptor. The company uses proprietary glycobiology technology to develop treatments for diseases. It also offers clinical research programs. GlycoMimetics is headquartered in Rockville, Maryland, the US.

GlycoMimetics Inc (GLYC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
GlycoMimetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
IAVI, GlycoMimetics, And Glycosensors and Diagnostics Enter Into Agreement To Develop AIDS Vaccine 11
Equity Offering 12
GlycoMimetics Prices Public Offering of Shares for USD119 Million 12
GlycoMimetics Raises USD92.6 Million in Public Offering of Shares 14
GlycoMimetics Raises USD21 Million in Public Offering of Shares 16
GlycoMimetics Raises USD3 Million in First Tranche of Public Offering of Shares 18
GlycoMimetics Completes IPO For US$64.4 Million 19
GlycoMimetics Inc – Key Competitors 21
GlycoMimetics Inc – Key Employees 22
GlycoMimetics Inc – Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Financial Announcements 24
Nov 02, 2018: GlycoMimetics reports third quarter 2018 results and highlights recent company achievements 24
Aug 09, 2018: Glycomimetics reports second quarter 2018 results and highlights recent company achievements 26
May 03, 2018: GlycoMimetics Reports First Quarter 2018 Results 27
Mar 06, 2018: GlycoMimetics Reports Fourth Quarter and Year-End 2017 Results 28
Nov 08, 2017: GlycoMimetics Reports Program Updates and Third Quarter 2017 Results 29
Aug 03, 2017: GlycoMimetics Reports Program Updates and Second Quarter 2017 Results 31
May 08, 2017: GlycoMimetics Reports Program Updates and First Quarter 2017 Results 33
Mar 01, 2017: GlycoMimetics Reports Fourth Quarter and Year-End 2016 Results 34
Corporate Communications 35
Jun 12, 2017: GlycoMimetics Appoints Boston Biomedical CEO Patricia S. Andrews to Its Board of Directors 35
Mar 13, 2017: GlycoMimetics Appoints Scott Koenig of MacroGenics to Board of Directors 36
Product News 37
06/05/2017: GlycoMimetics Presents Updated Data from Ongoing Phase 1/2 Clinical Trial of GMI-1271 in Patients with Acute Myeloid Leukemia at ASCO 2017 Annual Meeting 37
05/17/2017: GlycoMimetics’ GMI-1271 Receives FDA Breakthrough Therapy Designation for Adult Relapsed/Refractory Acute Myeloid Leukemia 38
Product Approvals 39
May 25, 2017: GlycoMimetics’ GMI-1271 Receives EU Orphan Drug Designation for Acute Myeloid Leukemia 39
Clinical Trials 40
May 30, 2018: GlycoMimetics Announces NCI-Sponsored Pivotal Trial of GMI-1271 in Older, Newly Diagnosed AML Patients Fit for Intensive Chemotherapy 40
Mar 14, 2018: GlycoMimetics to Present New Preclinical Data for GMI-1271 at AACR Annual Meeting 2018 41
Mar 14, 2018: GlycoMimetics to Present New Preclinical Data for GMI-1359 at AACR Annual Meeting 2018 42
Mar 05, 2018: GlycoMimetics Announces Design of Phase 3 Clinical Trial for GMI-1271 in Relapsed/Refractory AML 43
Feb 08, 2018: GlycoMimetics Enters into Agreement with HOVON to Initiate Study Startup Activities for Planned Clinical Trial of GMI-1271 and Decitabine in Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Chemotherapy 44
Dec 12, 2017: GlycoMimetics Reports Improvements in Median Overall Survival Versus Historical Matched Controls for Two AML Patient Subgroups in Phase 1/2 Trial for GMI-1271 45
Nov 01, 2017: GlycoMimetics to Highlight GMI-1271 Clinical Data and Underlying, Differentiated Mechanism of Action in Oral Presentations at 59th Annual ASH Meeting 46
May 18, 2017: GlycoMimetics Announces High Overall Response Rates, Low Induction Mortality, Promising Initial Survival Outcomes, and Supportive Biomarker Data from Phase 1/2 Trial of GMI-1271 in AML 48
May 02, 2017: GlycoMimetics Announces Publication of Preclinical Data Showing Role of E-selectin Ligands in Multiple Myeloma 50
Apr 20, 2017: GlycoMimetics to Present New AML Clinical Data at ASCO 2017 Annual Meeting 51
Mar 07, 2017: GlycoMimetics Completes Enrollment of Newly Diagnosed AML Patient Cohort in Phase 2 Clinical Trial of GMI-1271 52
Mar 02, 2017: GlycoMimetics to Present New Preclinical Data of GMI-1271 at AACR Annual Meeting 2017 53
Mar 02, 2017: GlycoMimetics to Present New Preclinical Data of GMI-1359 at AACR Annual Meeting 2017 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55

List of Tables
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
GlycoMimetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
GlycoMimetics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
IAVI, GlycoMimetics, And Glycosensors and Diagnostics Enter Into Agreement To Develop AIDS Vaccine 11
GlycoMimetics Prices Public Offering of Shares for USD119 Million 12
GlycoMimetics Raises USD92.6 Million in Public Offering of Shares 14
GlycoMimetics Raises USD21 Million in Public Offering of Shares 16
GlycoMimetics Raises USD3 Million in First Tranche of Public Offering of Shares 18
GlycoMimetics Completes IPO For US$64.4 Million 19
GlycoMimetics Inc, Key Competitors 21
GlycoMimetics Inc, Key Employees 22

List of Figures
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[GlycoMimetics Inc (GLYC)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • SurgaColl Technologies Ltd：医療機器：M&Aディール及び事業提携情報
    Summary SurgaColl Technologies Ltd (SurgaColl Technologies) is a medical device company that develops novel tissue regeneration products for the surgical treatment of disease of the bone, cartilage and other human tissue. The company’s products include hydroxycoll and chondrocoll. Its hydroxycoll is …
  • Hansol Logistics Co., Ltd. (009180)：企業の財務・戦略的SWOT分析
    Hansol Logistics Co., Ltd. (009180) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Fenner PLC (FENR)：企業の財務・戦略的SWOT分析
    Summary Fenner PLC (Fenner), a subsidiary of Michelin SCA, is a provider of reinforced polymer technology. The company operates in the areas of advanced engineered products and engineered conveyor solutions. Its product portfolio includes heavyweight conveyor belt, high performance polymer component …
  • Interpace Diagnostics Group Inc (IDXG)-医療機器分野：企業M&A・提携分析
    Summary Interpace Diagnostics Group Inc (Interpace Diagnostics), formerly PDI Inc, is a developer of molecular diagnostics tests. The company offers PancraGen, a DNA based molecular test that aids in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its pathfinder platform; a …
  • Intersurgical Ltd.：企業の戦略的SWOT分析
    Intersurgical Ltd. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Daidalos Solutions BV：企業の製品パイプライン分析2018
    Summary Daidalos Solutions BV (Daidalos Solutions) is a medical device company. The company offers products such as sutureless biological heart valve prostheses, sutureless mechanical heart valve prostheses, sutureless heart valve repair rings, sutureless working channels and ports, sutureless closi …
  • Toyo Tire & Rubber Co Ltd (5105)：企業の財務・戦略的SWOT分析
    Toyo Tire & Rubber Co Ltd (5105) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Sutures India Pvt Ltd-医療機器分野：企業M&A・提携分析
    Summary Sutures India Private Limited (SIPL) is a medical device company that manufactures and markets surgical sutures. The company provides absorbable sutures, surgical tape, surgical mesh, bone wax, nonabsorbable sutures, skin stapler and surgical gloves. Its absorbable sutures include plain catg …
  • Burmeister & Wain Scandinavian Contractor AS：企業の戦略的SWOT分析
    Burmeister & Wain Scandinavian Contractor AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors …
  • Mizuho Trust & Banking Co Ltd：企業の戦略・SWOT・財務情報
    Mizuho Trust & Banking Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Mizuho Trust & Banking Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Claret Medical Inc：医療機器：M&Aディール及び事業提携情報
    Summary Claret Medical Inc (Claret Medical), a subsidiary of Boston Scientific Corp develops and commercializes cerebral protection systems. The company offers medical devices for cerebral protection during structural heart and vascular interventions, and cardiac surgery procedures. Its lead product …
  • Amoy Diagnostics Co Ltd (300685)：医療機器：M&Aディール及び事業提携情報
    Summary Amoy Diagnostics Co Ltd (AmoyDx) is a developer of molecular diagnostics for oncology precision medicine. The company provides gene mutation products such as mutation detection kit and gene fusions detection kit. It offers nucleic acid extraction products including DNA and RNA extraction kit …
  • EBSCO Industries Inc.：企業の戦略・SWOT・財務分析
    EBSCO Industries Inc. - Strategy, SWOT and Corporate Finance Report Summary EBSCO Industries Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Localiza Rent A Car SA：企業の戦略・SWOT・財務情報
    Localiza Rent A Car SA - Strategy, SWOT and Corporate Finance Report Summary Localiza Rent A Car SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Hybrigenics SA (ALHYG)：企業の財務・戦略的SWOT分析
    Hybrigenics SA (ALHYG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Ethicon US LLC：企業の戦略的SWOT分析
    Ethicon US LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • China Grand Pharmaceutical and Healthcare Holdings Ltd (512)：企業の財務・戦略的SWOT分析
    Summary China Grand Pharmaceutical and Healthcare Holdings Ltd (China Grand) is an investment holding company that develops, manufacture and distributes pharmaceutical preparations, medical devices and pharmaceutical intermediates, specialized raw materials, and healthcare products. The company prov …
  • Isuzu Motors Ltd (7202)：企業の財務・戦略的SWOT分析
    Isuzu Motors Ltd (7202) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • LifeWatch AG (LIFE)-医療機器分野：企業M&A・提携分析
    Summary LifeWatch AG (LifeWatch) is a healthcare technology and solutions company. It provides monitoring services and develops, manufactures, and markets advanced telehealth systems for high-risk and chronically ill patients. The company’s major services include mobile cardiac telemetry service, st …
  • John Keells Hotels Plc
    John Keells Hotels Plc - Strategy, SWOT and Corporate Finance Report Summary John Keells Hotels Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆